IPO registrations (S-1, F-1) · Registrants
Omrix Biopharmaceuticals, Inc.
- SEC CIK
- 1349426 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2006-01-18, last 2006-12-11; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2006-04-21; declared effective 2006-12-14
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 630 FIFTH AVENUE, 22ND FLOOR, New York, NY 10111
- EIN
- 52-2147005
- EDGAR entity type
- operating
- Insiders and CEO pay
- Omrix Biopharmaceuticals, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2006-04-07)
- Final price
- $8.46 per share, below the range (424B4 filed 2006-04-21, an initial public offering)
- Shares sold
- 3,437,500
- Gross proceeds
- $29,081,250 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol OMRI
- Lead underwriters
- UBS; CIBC World Markets (945,313 shares); Leerink Partners (429,687 shares); Oppenheimer (343,750 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: OMRIX BIOPHARMACEUTICALS INC EXACT (EIN (EXACT))
- SEC filer: Omrix Biopharmaceuticals, Inc. EXACT (CIK (EXACT))
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-01-18 | S-1 | S-1 (registration) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-000462 ↗ |
| 2006-03-08 | S-1/A | S-1/A (amendment) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-002795 ↗ |
| 2006-03-24 | S-1/A | S-1/A (amendment) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-003659 ↗ |
| 2006-04-07 | S-1/A | S-1/A (amendment) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-004381 ↗ |
| 2006-04-21 | 424B4 | 424B4 (final prospectus) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-004920 ↗ |
| 2006-12-04 | S-1 | S-1 (registration) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-014784 ↗ |
| 2006-12-11 | S-1/A | S-1/A (amendment) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-015014 ↗ |
| 2006-12-14 | EFFECT | EFFECT (declared effective) | Omrix Biopharmaceuticals, Inc. | 9999999995-06-002713 ↗ |
| 2006-12-15 | 424B4 | 424B4 (final prospectus) | Omrix Biopharmaceuticals, Inc. | 0000950123-06-015237 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2006-04-07 | S-1/A | registration statement | $15.00–$17.00 | 3,437,500 | - | Nasdaq OMRI | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2006-04-21 | 424B4 | final prospectus | $8.46 | 3,437,500 | $29,081,250 | Nasdaq OMRI | 4 | primary document; price line, shares headline, proceeds computed, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BAB BIO VENTURES LLP | Other; TenPercentOwner | 3 | 2006 | ||
| BAB BIO VENTURES NV | Other; TenPercentOwner | 3 | 2006 | ||
| BB BIOVENTURES L P | Other; TenPercentOwner | 3 | 2006 | ||
| Burshtine Michael | Officer; Other | Senior Vice President, CFO; Senior VP and CFO | 9 | 2006–2008 | |
| COTTER DOUGLAS A | Director | 3 | 2006 | ||
| EVNIN LUKE | Other; TenPercentOwner | 4 | 2006 | ||
| GADICKE ANSBERT | Other; TenPercentOwner | 4 | 2006 | ||
| Horowitz Bernard | Director | 11 | 2006–2008 | ||
| Mashiach Nissim | Officer | President and COO; Senior V.P., Operations; Senior VP, Operations | 7 | 2006–2008 | |
| MEDICAL PORTFOLIO MANAGEMENT LLC | TenPercentOwner | 2 | 2006 | ||
| MPM ASSET MANAGEMENT INVESTORS 1998 LLC | Other; TenPercentOwner | 3 | 2006 | ||
| MPM BIO VENTURES I LLC | Other; TenPercentOwner | 3 | 2006 | ||
| MPM BIOVENTURES I LP | Other; TenPercentOwner | 3 | 2006 | ||
| MPM BIOVENTURES PARALLEL FUND L P | Other; TenPercentOwner | 3 | 2006 | ||
| MPM CAPITAL LP | TenPercentOwner | 2 | 2006 | ||
| PRICE FREDRIC D | Director | 5 | 2006–2007 | ||
| Romagnoli Philippe | Director; Officer | Vice President and Secretary | 7 | 2006–2008 | |
| SAFFERSTEIN HAROLD | Director; Officer | VP, Business Development | 4 | 2006–2007 | |
| STEINMETZ MICHAEL | Other; TenPercentOwner | 3 | 2006 | ||
| St Peter Steven | Director | 5 | 2006–2008 | ||
| Taub Robert | Director,Officer | Chief Executive Officer; Pres., Chief Executive Officer | 6 | 2006–2008 | |
| ELLBERGER LARRY | Director | 4 | 2006–2008 | ||
| Prado Nanci | Officer | General Counsel; Vice Pres. & General Counsel; V.P. & General Counsel | 3 | 2006–2007 | |
| Akers Joseph A | Director | 2 | 2006 | ||
| RAKIN KEVIN | Director | 5 | 2007–2008 | ||
| Tang Joseph | Officer | General Manager, Asia | 2 | 2007 | |
| Bokel Georg | Officer | General Manager, Germany | 1 | 2007 | |
| Stancic Ana | Officer | Chief Financial Officer | 2 | 2007 | |
| Droppert V. Marc | Officer | Executive Vice President | 3 | 2007–2008 | |
| MCNAMARA PAMELA W | Director | 2 | 2008 | ||
| Alperovitz Asaf | Officer | Chief Financial Officer | 2 | 2008 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Omrix Biopharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | OMRIX BIOPHARMACEUTICALS INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NY first:
- Acorda Therapeutics, Inc. NY
- BRAINSTORM CELL THERAPEUTICS INC. NY
- ANAVEX LIFE SCIENCES CORP. NY
- CytRx Oncology Corp NY
- Protara Therapeutics, Inc. NY
- COGNITION THERAPEUTICS INC NY
- Bavarian Nordic A/S / ADR NY
- Qrons Inc. NY
- Prevail Therapeutics Inc. NY
- MeiraGTx Holdings plc NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health